The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
In a recent article published on Pharmaceutical Executive, we explore The Most-Favored-Nation Policy; it’s Outlook and Implications Beyond U.S.
German Drug Pricing Reforms: What do they mean for P&MA?
This article will describe the cost-containment measures introduced by the new government and how they influence drugs’ pricing and market access potential.